Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eciskafusp alfa
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intravesical
01
Overview
Eciskafusp alfa is a recombinant fusion protein immunocytokine that combines an interleukin-2 variant (IL2v) with an anti-PD1 protein moiety. It is designed to preferentially target PD-1–expressing T cells, particularly antigen-specific stem-like PD-1+ TCF-1+ CD8+ T cells, expanding and differentiating them into more effective effector T cells. The IL2v component stimulates local immune responses by activating natural killer (NK) cells and cytotoxic T lymphocytes, while the anti-PD1 moiety blocks the programmed cell death 1 receptor (PD‑1), enhancing antitumor immunity. Eciskafusp alfa is being developed primarily for advanced or metastatic solid tumors responsive to checkpoint inhibition blockade and has also entered trials for non-muscle invasive bladder cancer in combination with Bacillus Calmette–Guérin (BCG). The drug was originated and is being developed by Roche/Hoffmann-La Roche[3][8][2][4].
- Other names
- eciskafusp alfa
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on eciskafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eciskafusp alfa.